

MYLAN LABORATORIES INC

Form 8-K

July 15, 2005

**Table of Contents**

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15 (d) OF  
THE SECURITIES EXCHANGE ACT OF 1934**

Date of Report (Date of earliest event reported): **July 15, 2005**

**MYLAN LABORATORIES INC.**

(Exact name of registrant as specified in its charter)

**Pennsylvania**  
(State or other  
jurisdiction of  
Incorporation)

**1-9114**  
(Commission File  
Number)

**25-1211621**  
(I.R.S. Employer  
Identification No.)

**1500 Corporate Drive**  
**Canonsburg, PA 15317**  
(Address of principal executive offices)

**(724) 514-1800**  
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**TABLE OF CONTENTS**

Item 8.01 Other Events.

Item 9.01 Financial Statements and Exhibits.

SIGNATURE

EXHIBIT INDEX

Exhibit 99.1

---

**Table of Contents**

**Item 8.01 Other Events.**

On July 15, 2005, Mylan Laboratories Inc. issued a press release announcing its pricing of \$150 million aggregate principal amount of its 5-3/4% Senior Notes due 2010 and \$350 million aggregate principal amount of its 6-3/8% Senior Notes due 2015. A copy of the press release is attached as Exhibit 99.1.

**Item 9.01 Financial Statements and Exhibits.**

(c) Exhibits.

Exhibit No.	Description
99.1	Press release of Mylan Laboratories Inc., dated July 15, 2005.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

MYLAN LABORATORIES INC.

Date: July 15, 2005

By: /s/ Edward J. Borkowski  
Edward J. Borkowski  
Chief Financial Officer

---

**Table of Contents**

**EXHIBIT INDEX**

Exhibit No.	Description
99.1	Press release of Mylan Laboratories Inc., dated July 15, 2005.